• About us
• Contact

Advertisement

Organisation › Details

Asahi Kasei (Group)

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care. Its Material sector, comprised of Environmental Solutions, Mobility & Industrial, and Life Innovation, includes a wide array of products from battery separators and biodegradable textiles to engineering plastics and sound solutions. *

 

	Start	1922-01-01 established
	Industry	CHEMICALS
	Industry 2	pharmaceutical
	Person	Kobori, Hideki (Asahi Kasei 201709 President + Representative Director of Asahi Kasei Corp)
	Region	Tokyo
	Country	Japan
	City	Tokyo
		Address record changed: 2024-04-12
Basic data	Employees	H: 10,001 to 50,00 (2024-04-11)
		* Document for »About Section«: Asahi Kasei Bioprocess. (4/11/24). "Press Release: Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development". Düsseldorf, Tokyo & New York, NY.
		Record changed: 2025-02-10

Advertisement

More documents for Asahi Kasei (Group)

• [1] PeptiSystems AB. (5/15/25). "Press Release: PeptiSystems and Asahi Kasei Bioprocess America Enter Exclusive Global Partnership for Peptide Synthesis". Uppsala....
• [2] Bionova Scientific. (6/3/24). "Press Release: Bionova Scientific Announces Plans for New Plasmid DNA GMP Facility". Fremont, CA....
• [3] Asahi Kasei Corporation. (5/28/24). "Press Release: Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company"....
• [4] Asahi Kasei Bioprocess. (4/11/24). "Press Release: Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development". Düsseldorf, Tokyo & New York, NY....
• [5] VectivBio Holding AG. (3/13/23). "Press Release: VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan". Basel....
• [6] VectivBio Holding AG. (3/30/22). "Press Release: VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts". Basel....
• [7] Memo Therapeutics AG. (7/6/21). "Press Release: Memo Therapeutics AG Appoints Seasoned Executives Elias Papatheodorou as Chairman and Dr. Thomas Taapken as Member to Board of Directors". Schlieren....
• [8] Calliditas Therapeutics AB. (8/25/20). "Press Release: Calliditas Appoints Group General Counsel"....
• [9] Calliditas Therapeutics AB. (8/13/20). "Press Release: Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA"....
• [10] Calliditas Therapeutics AB. (7/24/20). "Press Release: Calliditas Reorganizes Its Management Team"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.